Popular on EntSun
- Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick - 246
- Donna Cardellino Manager/Facilitator Signs Justin Jeansonne Country Singer-Songwriter To Exclusive Management Deal For Global Music Expansion - 156
- VDG Virtuoso Emerges as a New-Model Independent Industry Figure Blending Artist, Executive, and Infrastructure Builder - 149
- Oliver Sean's "Everyday Will Be Like A Holiday" Featuring the Real Indie Project Hits #1 in Portugal on Christmas Eve - 126
- UK Financial Ltd Executes Compliance Tasks Ahead Of First-Ever ERC-3643 Exchange-Traded Token, SMCAT & Sets Date For Online Investor Governance Vote - 125
- Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow - 115
- Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence - 114
- "Phinge Unveil™" Coming to Las Vegas to Showcase Netverse Patented Verified App-less Platform, AI & Modular Hardware Including Developer Conferences - 111
- Renowned Alternative Medicine Specialist Dr. Sebi and His African Bio Mineral Balance Therapy Are the Focus of New Book - 110
- IQSTEL Enters 2026 from a Position of Strength Following Transformational Year Marked by N A S D A Q Uplisting, Record Revenue and First-Ever - 108
Similar on EntSun
- High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
- AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
- Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
- $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
- $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
- U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
Cedience Launches Cedience Labs to Empower Regulatory Teams with AI-Powered Workflows
EntSun News/11082098
New platform enables regulatory professionals to experiment with cutting-edge AI tools while preserving established workflows
ST. CATHARINES, Ontario - EntSun -- Cedience, the regulatory-first AI company supporting drug development teams with innovative research and intelligence technology, today announced the launch of Cedience Labs, a new platform enabling teams to experiment with cutting-edge, AI-powered tools that support decision-making at critical points in drug development.
Cedience Labs provides a secure environment where regulatory teams can explore advanced AI capabilities—particularly large language model (LLM) technologies—without disrupting existing processes or enterprise systems. The platform reflects Cedience's commitment to enabling regulatory organizations to modernize their toolkits with a value-first approach, grounded in real-world regulatory use cases.
"The biopharmaceutical industry is rapidly adopting AI and LLM-based technologies, with many enterprise-wide initiatives well underway," said Amin Osmani, CEO of Cedience. "Cedience Labs was created to give regulatory professionals a practical way to engage with these innovations without delay—allowing them to enhance their workflows, not replace them."
More on EntSun News
Re-inventing the Regulatory Toolbox
Regulatory teams face increasing complexity as global health authorities and their guidelines or requirements evolve with the industry. Cedience Labs addresses this challenge by enabling hands-on experimentation with AI-driven tools that align with how regulatory work is actually performed.
Through Cedience Labs, regulatory professionals can explore AI-supported workflows such as:
All workflows are designed to integrate seamlessly into existing regulatory processes, allowing teams to enhance efficiency and insight without operational disruption.
Built for Today's AI-Enabled Enterprise
As AI adoption accelerates across biopharma, Cedience Labs offers a pragmatic bridge between experimentation and enterprise readiness. The platform enables regulatory teams to evaluate emerging AI capabilities, understand their value, and build confidence before broader organizational deployment.
More on EntSun News
"Our team has built the AI building blocks regulatory teams need to capture the value from LLMs without complex development cycles," said Andy Nanopoulos, CTO of Cedience. "Cedience Labs provides modular, workflow-ready components that can be applied directly to real regulatory questions, allowing teams to move from experimentation to impact quickly and responsibly."
By abstracting the complexity of large language models and embedding them into familiar regulatory workflows, Cedience Labs helps organizations realize value from AI while maintaining governance, traceability, and alignment with existing operating models. Regulatory teams can incrementally enhance their capabilities, test new approaches, and scale successful use cases at their own pace.
For more information about Cedience and its regulatory intelligence solutions, visit www.cedience.com
Cedience Labs provides a secure environment where regulatory teams can explore advanced AI capabilities—particularly large language model (LLM) technologies—without disrupting existing processes or enterprise systems. The platform reflects Cedience's commitment to enabling regulatory organizations to modernize their toolkits with a value-first approach, grounded in real-world regulatory use cases.
"The biopharmaceutical industry is rapidly adopting AI and LLM-based technologies, with many enterprise-wide initiatives well underway," said Amin Osmani, CEO of Cedience. "Cedience Labs was created to give regulatory professionals a practical way to engage with these innovations without delay—allowing them to enhance their workflows, not replace them."
More on EntSun News
- Day-to-Day Work of NOLA's Royal Family of Music, The Batistes, Continues Embracing Legacy & Vision
- Mama Vlada Award-Winning Documentary Playing at Historic Kent Theater, Brooklyn February 6–12, 2026
- Shaken, Not Stirred: Joseph Neibich Nybyk on Mixing Hollywood Spectacle with Stand-Up Soul
- Kadesmode Reaches Top 50% of Global Songwriters Following Chart-Topping Debut R&B Music
- NYCSS Wants You to Unlock Your Inner Jedi
Re-inventing the Regulatory Toolbox
Regulatory teams face increasing complexity as global health authorities and their guidelines or requirements evolve with the industry. Cedience Labs addresses this challenge by enabling hands-on experimentation with AI-driven tools that align with how regulatory work is actually performed.
Through Cedience Labs, regulatory professionals can explore AI-supported workflows such as:
- Monitoring and interpreting changes in the global regulatory environment
- Assessing the potential impact of regulatory updates
- Establishing regulatory precedents across indications, regions, and products
- Preparing for agency meetings and interactions
- Analyzing and benchmarking regulatory review timelines
All workflows are designed to integrate seamlessly into existing regulatory processes, allowing teams to enhance efficiency and insight without operational disruption.
Built for Today's AI-Enabled Enterprise
As AI adoption accelerates across biopharma, Cedience Labs offers a pragmatic bridge between experimentation and enterprise readiness. The platform enables regulatory teams to evaluate emerging AI capabilities, understand their value, and build confidence before broader organizational deployment.
More on EntSun News
- Boston Corporate Coach™ Sets Global Standard for Executive Chauffeur Services Across 680 Cities
- UK Financial Ltd Announces CoinMarketCap Supply Verification And Market Positioning Review For Regulated Security Tokens SMPRA And SMCAT
- Sharpe Automotive Redefines Local Car Care with "Transparency-First" Service Model in Santee
- BEST DRESSED & RISE AND FALL Premiere January 30 on Cpics.tv
- Gold Viddy Award Honors Voices for Humanity Episode on Education Reform in Ghana
"Our team has built the AI building blocks regulatory teams need to capture the value from LLMs without complex development cycles," said Andy Nanopoulos, CTO of Cedience. "Cedience Labs provides modular, workflow-ready components that can be applied directly to real regulatory questions, allowing teams to move from experimentation to impact quickly and responsibly."
By abstracting the complexity of large language models and embedding them into familiar regulatory workflows, Cedience Labs helps organizations realize value from AI while maintaining governance, traceability, and alignment with existing operating models. Regulatory teams can incrementally enhance their capabilities, test new approaches, and scale successful use cases at their own pace.
For more information about Cedience and its regulatory intelligence solutions, visit www.cedience.com
Source: Cedience Inc.
0 Comments
Latest on EntSun News
- CryptaBox Introduces a Hardware Crypto Cold Storage Wallet
- YWWSDC Launches AI-Native Digital Asset Infrastructure, Merging Technical Innovation with US-Standard Compliance
- NYC Comedian Rafael Gee Announces New Memoir "Mi Vida Loca: Tales of a NuyoRican"
- Yesyal Launches Official Website, Unifying Music, Film, and Apparel Under One Independent Brand
- Avalex, LP & Avalex Ent Announces Professional Services and Evaluations for Entertainment, Sports
- High-End Exterior House Painting in Boulder, Colorado
- Meet a Scientologist Grills Up Gold Viddy Award for Japan's Gourmet Burger Pioneer Akio Kitaura
- Simpson and Reed Co-Founders Shardé Simpson, Esq. and Ciara Reed, Esq. Launch "Hello Wilma,"
- Report Outlines Key Questions for Individuals Exploring Anxiety Treatment Options in Toronto
- Rande Vick Introduces Radical Value, Challenging How Brands Measure Long-Term Value
- Lisa Mauretti Launches Peace of Mind Travel Coaching to Guide Fearful Travelers to Discover the World with Confidence
- New Year, New Home: Begin 2026 at Heritage at South Brunswick
- Higginswerx Honored as Winner in FlovaAI Christmas Creator Challenge
- Food Journal Magazine Releases Its 'Best Food In Los Angeles Dining' Editorial Section
- Enders Capital: 25% Gains with Just -0.80% Maximum Monthly Drawdown in Volatile Debut Year 2025
- Max Weinberg Brings His Max Weinberg's Jukebox to the Weinberg Center
- Venture Beyond the Ordinary in "AJ AND THE INCREDIBLE FISH" by Paolo Mazzucato
- CES Spotlight Highlights Need for Strategic Review as Throughput Demands Evolve
- ASR Media, Social T Marketing & PR Announce Merger
- $780,000 Project for New Middle East Police Service with Deposit Received and Preliminary Design Work Underway for Lamperd: Stock Symbol: LLLI